Inhibition of leydig tumor growth by farnesoid X receptor activation: The in vitro and in vivo basis for a novel therapeutic strategy

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2237-2247

  Catalano, Stefania ^a   Panza, Salvatore ^a   Malivindi, Rocco ^a   Giordano, Cinzia ^a   Barone, Ines ^a   Bossi, Gianluca ^b   Lanzino, Marilena ^a   Sirianni, Rosa ^a   Mauro, Loredana ^a   Sisci, Diego ^a   Bonofiglio, Daniela ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

apoptosis; Farnesoid X receptor; Leydig tumors; NF kB; p53

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; AROMATASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; FARNESOID X RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FRAGMENTATION; GEL MOBILITY SHIFT ASSAY; IN VITRO STUDY; IN VIVO STUDY; LEYDIG CELL TUMOR; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AROMATASE; CELL PROLIFERATION; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; ISOXAZOLES; LEYDIG CELL TUMOR; MALE; MICE; MICE, NUDE; NF-KAPPA B; P21-ACTIVATED KINASES; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TESTICULAR NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874944427     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27915     Document Type: Article

References (50)

1. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-93.
2. Otte K, Kranz H, Kober I, et al. Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 2003; 23: 864-72.
3. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-65.
4. Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003; 11: 1079-92.
5. Modica S, Gadaleta RM, Moschetta A,. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010; 8: 1-28.
6. Koutsounas I, Giaginis C, Theocharis S,. Farnesoid X receptor (FXR) from normal to malignant state. Histol Histopathol 2012; 27: 835-53.
7. De Gottardi A, Touri F, Maurer CA, et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004; 49: 982-89.
8. Modica S, Murzilli S, Salvatore L, et al. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res 2008; 68: 9589-94.
9. Dai J, Wang H, Shi Y, et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol 2011; 4: 41
10. Maran RR, Thomas A, Roth M, et al. FXR deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 2009; 328: 469-77.
11. Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28: 940-46.
12. Yang F, Huang X, Yi T, et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67: 863-67.
13. Swales KE, Korbonits M, Carpenter R, et al. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 2006; 66: 10120-26.
14. Giordano C, Catalano S, Panza S, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 2011; 30: 4129-40.
15. De Gottardi A, Dumonceau JM, Bruttin F, et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer 2006; 5: 48.
16. Lee JY, Lee KT, Lee JK, et al. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Brit J Cancer 2011; 104: 1027-37.
17. Catalano S, Malivindi R, Giordano C, et al. Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J Biol Chem 2010; 285: 5581-93.
18. Hawkins C, Miaskowski C,. Testicular cancer: a review. Oncol Nurs Forum 1996; 23: 1203-11.
19. Fowler KA, Gill K, Kirma N, et al. Overexpression of aromatase leads to development of testicular Leydig cell tumors: an in vivo model for hormone-mediated testicular cancer. Am J Pathol 2000; 156: 347-53.
20. Sirianni R, Chimento A, Malivindi R, et al. Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation. Cancer Res 2007; 67: 8368-77.
21. Carpino A, Rago V, Pezzi V, et al. Detection of aromatase and estrogen receptors (ERα, ERβ1, ERβ2) in human Leydig cell tumor. Eur J Endocrinol 2007; 157: 239-44.
22. Straume AH, Løvås K, Miletic H, et al. Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. Eur J Endocrinol 2012; 166: 941-49
23. McCluggage WG, Shanks JH, Arthur K, et al. Cellular proliferation and nuclear ploidy assessment augment established prognmostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology 1993; 33: 361-68.
24. Qin C, Nguyen T, Stewart J, et al. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kB/CCAAT-binding transcription factor-1 complex. Mol Endocrinol 2002; 16: 1793-1809.
25. Mauro L, Catalano S, Bossi G, et al. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res 2007; 67: 3412-21.
26. Catalano S, Pezzi V, Chimento A, et al. Triiodothyronine (T3) decreases the activity of the proximal promoter (PII) of the aromatase gene in the mouse Sertoli cell line, TM4. Mol Endocrinol 2003; 17: 923-34.
27. Catalano S, Barone I, Giordano C, et al. Rapid estradiol/ERα signaling enhances aromatase enzymatic activity in breast cancer cells. Mol Endocrinol 2009; 23: 1634-45.
28. Morelli C, Garofalo C, Sisci D, et al. Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene 2004; 23: 7517-26.
29. Bonofiglio D, Gabriele S, Aquila S, et al. Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Res Treat 2009; 113: 423-34.
30. Lanzino M, Sisci D, Morelli C, et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells. Identification of a novel androgen response element. Nucleic Acids Res 2010; 16: 5351-65.
31. Sisci D, Middea E, Morelli C, et al. 17β-estradiol enhances α5 integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα positive breast cancer cells. Breast Cancer Res Treat 2010; 124: 63-77.
32. Catalano S, Rizza P, Gu G, et al. Fas ligand expression in TM4 sertolo cells is enhanced by estradiol "in situ" production. J Cell Physiol 2007; 211: 448-56.
33. Li G, Thomas AM, Williams JA, et al. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One 2012; 7: e35895.
34. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 23: 6304-11.
35. Levine AJ,. p53, the cellular gatekeeper for growth and division. Cell 1997; 3: 323-31.
36. Ohno T, Shirakami Y, Shimizu M, et al. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer Lett 2012; 323: 215-22.
37. Haupt S, Berger M, Goldberg Z, et al. Y. Apoptosis-the p53 network. J Cell Sci 2003; 15: 4077-85.
38. Schuler M, Green DR,. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684-88.
39. Yu J, Zhang L,. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 3: 851-58.
40. Sengupta S, Wasylyk B,. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann N Y Acad Sci 2004; 1024: 54-71.
41. Gu G, Barone I, Gelsomino L, et al. Oldenlandia Diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation. J Cell Physiol 2012; 227: 3363-72.
42. Laffitte BA, Kast HR, Nguyen CM, et al. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000; 275: 10638-47.
43. Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 28857-65.
44. Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002; 109: 961-71.
45. Kalaany NY, Mangelsdorf DJ,. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Ann Rev Physiol 2006; 68: 159-91.
46. Chen LF, Greene WC,. Shaping the nuclear action of NF-KappaB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
47. Perkins ND, Gilmore TD,. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006; 13: 759-72.
48. Radhakrishanan SK, Kamalakaran S,. Proapoptotic role of NF-kB: implication for cancer therapy. Biochim Biophys Acta 2006; 1766: 53-62.
49. Ryan KM, Ernst KE, Rice NR, Vousden KH,. Role of NF-kB in p53-mediated programmed cell death. Nature 2000; 404: 892-96.
50. Joo JH, Jetten AM,. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett 2010; 287: 123.